PSA is organ specific and not tumor specific. Explain according to ROB

PSA is organ specific and not tumor specific. Explain according to ROBBINS BOOK FOR PATHOLOGY 2nd MBBS

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the content I need from both Robbins books. Let me compose the full, well-cited answer.

PSA is Organ Specific, Not Tumor (Cancer) Specific

What is PSA?

Prostate-Specific Antigen (PSA) is a serine protease produced by the epithelial cells of the prostate gland. It is normally secreted into semen, where its function is to cleave and liquefy the seminal coagulum formed after ejaculation, allowing for the slow release of sperm. In healthy males, only minute quantities of PSA circulate in the blood.

Robbins & Kumar Basic Pathology (Robbins Pathology), Chapter 16 (Prostate)
Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 21 (Prostate)

"Organ Specific" - What Does This Mean?

PSA is produced exclusively by prostatic epithelium - it is not made by any other organ in the body. This makes it organ specific: wherever PSA is detected (even in metastatic deposits), it reliably identifies the prostate as the organ of origin.

As stated directly in Robbins, Cotran & Kumar (Pathologic Basis of Disease):

"PSA is organ specific, but not cancer specific."

This single line, which appears verbatim in Robbins, is the core of the concept being asked here.

"Not Tumor (Cancer) Specific" - Why?

PSA is elevated not only in prostate cancer, but also in several non-malignant (benign) conditions. This is why PSA is NOT tumor-specific. The following causes of PSA elevation are described in Robbins:

Condition	Mechanism of PSA Elevation
Prostate Cancer (Carcinoma)	Malignant epithelial cells produce excess PSA, which leaks into circulation
Benign Prostatic Hyperplasia (BPH)	Increased number of normal prostatic glandular cells increases total PSA output
Prostatitis	Inflammation disrupts the prostate-blood barrier, allowing PSA to leak
Prostate gland infarction (e.g., in BPH)	Tissue damage increases PSA release into blood
Instrumentation of the prostate	Physical manipulation (biopsy, catheterization) releases PSA
Ejaculation	Transiently raises serum PSA

From Robbins, Cotran & Kumar (Pathologic Basis of Disease):

"Although serum levels of PSA are elevated on average to a lesser extent in patients with BPH than in those with prostate cancer, there is considerable overlap in these two groups of patients. Other factors such as prostatitis, prostate gland infarction (e.g., in the setting of BPH), instrumentation of the prostate, and ejaculation also increase serum PSA levels."

From Robbins & Kumar Basic Pathology:

"PSA levels may be elevated in a variety of benign conditions (e.g., prostatitis, or following instrumentation of the prostate)."

Consequences for Clinical Use - What Robbins Says

Because PSA is organ specific but not cancer specific, it has important limitations as a screening test:

1. Low Specificity:

A raised PSA does not necessarily mean cancer - BPH, prostatitis, and other benign conditions can produce the same result.
There is considerable overlap between PSA levels in BPH patients and prostate cancer patients.

2. Low Sensitivity:

Conversely, prostate cancer can exist even with PSA within the normal range.
Robbins Basic Pathology notes: "20% to 40% of patients with organ-confined prostate cancer have PSA values below the cutoffs that identify individuals likely to have prostate cancer."

3. Controversy as a screening test:

Robbins Cotran notes: "As a result of these concerns, some countries with national health care systems (e.g., the United Kingdom) have recommended against using PSA as a screening test."
Robbins Basic states: "Large studies have shown that PSA screening has little or no impact on reducing prostate cancer mortality."

Where PSA IS Valuable

Despite its limitations as a screening tool, Robbins is clear that PSA has strong clinical value in:

Monitoring response to treatment - after radical prostatectomy or radiation, PSA should drop to undetectable levels.
Detecting recurrence - a rising PSA after treatment "almost always signifies recurrence."
Immunohistochemistry - PSA staining of metastatic deposits can confirm a prostatic primary even when the primary site is unknown (organ specificity is useful here).

From Robbins Basic Pathology:

"Detection of prostate-specific antigen (PSA) in metastatic deposits allows definitive diagnosis of a primary tumor in the prostate gland."

Summary Table

Property	PSA
Organ specific?	YES - only produced by prostatic epithelium
Tumor/Cancer specific?	NO - elevated in BPH, prostatitis, infarction, post-instrumentation, ejaculation
Useful for screening?	Controversial / limited (low sensitivity and specificity)
Useful for monitoring known cancer?	YES - serial PSA is the gold standard
Useful in immunohistochemistry?	YES - identifies prostatic origin of metastases

Sources:

Robbins & Kumar Basic Pathology (10th ed.), Chapter 16 (Prostate) and Chapter 7 (Tumor Markers)
Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 21 (Prostate) and Chapter 7 (Tumor Markers)

This is a shared conversation. Sign in to Orris to start your own chat.